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ABSTRACT 
Objective: Although osteoarthritis (OA) is widely accepted as a degenerative disease, auto-
immune processes are believed to be involved in the pathogenesis. There are limited studies 
in this area and most of them focused on antibodies against chondrocyte membrane. In an at-
tempt to address the paucity of evidence in this regard, we explored the clinical significance 
of antinuclear antibody (ANA) in primary osteoarthritis of the knee (OAK). 
Method: We studied 106 patients with primary osteoarthritis of at least 1 knee and 63 healthy 
controls from two tertiary centres in Malaysia from September 2005 to May 2012. All sub-
jects were tested for ANA by immunofluorescence testing, and a titer of 1:40 and above was 
considered positive. Besides, the radiographs of bilateral knees were evaluated for grading, 
tibiofemoral compartment involvement and total knee replacement (TKR) implants. We com-
pared the clinical characteristics between the ANA positive and ANA negative OAK cases. 
Results: The incidence of ANA positivity among the cases (39.4 %) was higher than the con-
trols (27 %) but this difference was statistically insignificant (p=0.754). ANA positive cases 
showed significantly higher incidence of bilateral and Grade IV OAK with higher frequency 
of TKR. In the multiple regression analysis, bilateral OAK (p< 0.0001; odds ratio 9.00), 
Grade IV OAK (p<0.001, odds ratio 3.44) and TKR (p=0.009; odds ratio 2.97) remained as-
sociated with ANA positivity. 
Conclusions: ANA test is a potential prognostic tool in primary OAK and its positivity is as-
sociated with the clinical outcomes of bilateral, Grade IV OAK and TKR.  
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INTRODUCTION 
The burden of osteoarthritis (OA) is on 
the rise with the steadily expanding aging 
population worldwide. It is disappointing 
that the treatment of this condition has not 
evolved much since its discovery centuries 
ago. Exploring the underlying mechanisms 
involved is of paramount importance to de-
velop novel therapies. Although OA is well 
established as a degenerative disease main-
ly caused by mechanical stresses and aging 
factors, the pathogenesis is probably more 
complex than previously thought. It was not 
until the 1980s that the concept of autoim-
munity in OA emerged (Cooke et al., 1980; 
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Jasin, 1985). From a research perspective, 
autoimmunity in OA has not received the 
attention it deserves. Hence, the available 
evidence on autoantibodies in OA are still 
far from being conclusive. 
Studies in the past on OA have reported 
humoral and cellular immune responses to 
cartilage-related components such as YKL-
39, cartilage intermediate layer protein, and 
osteopontin (Yuan et al., 2003; Mollenhau-
er et al., 1988; Tsuruha et al., 2002; Sakata 
et al., 2001). In fact, anti fibulin-4 directed 
against fibulin-4, which is an extracellular 
matrix protein was found to be more preva-
lent in OA than rheumatoid arthritis (RA) 
(Xiang et al., 2006). The limited studies re-
lated to autoimmunity in OA have mostly 
looked into antibodies against chondrocyte 
membrane (Jasin, 1985; Mollenhauer et al., 
1988; Tsuruha et al., 2002; Sakata et al., 
2001). 
Antinuclear antibody (ANA) is one of 
the most commonly performed screening 
tests in the detection of autoimmune diseas-
es. Although strongly associated with Sys-
temic Lupus Erythematosus, it is not highly 
specific for this condition. ANA is found in 
a wide array of autoimmune diseases en-
compassing connective tissue diseases like 
RA and non rheumatic diseases such as 
primary biliary cirrhosis, Graves disease 
and autoimmune hepatitis (Colglazier and 
Sutej, 2005). 
A few studies in the past have examined 
the incidence of ANA positivity among OA 
patients (Steven et al., 1984; Bonroy et al., 
2012; Gaddy et al., 2012). Although Steven 
et al. (1984) reported that 15 % of OA pa-
tients tested ANA positive, the role of ANA 
in this condition was not further explored. 
In 2009, Udartsev et al. discovered that in 
osteoarthrosis the frequency of chromoso-
mal aberrations correlated positively with 
the amount of ANA in the synoviocytes. 
However, till today there is still lack of 
published data on ANA in OA and hence, 
the clinical significance of ANA in this re-
gard remains largely undetermined. We hy-
pothesize that ANA positivity could be a 
factor influencing the severity of OA. The 
basis for this hypothesis is the well docu-
mented association between circulating au-
toantibodies and more aggressive course of 
disease in certain conditions such as rheu-
matoid arthritis and primary biliary cirrho-
sis. Autoantibodies have been postulated to 
trigger immune mediators of organ damage 
(Aletaha et al., 2012; Edelman and Russell 
1983; Rigopoulou et al., 2005). Hence, the 
aim of this study was to compare the clini-
cal characteristics of the ANA-positive with 
the ANA-negative OA of the knee patients. 
 
METHODS 
Patients 
We studied 106 patients with primary 
osteoarthritis of at least 1 knee (the cases) 
and 63 healthy controls from two tertiary 
centres in Malaysia i.e Universiti Kebang-
saan Malaysia Medical Centre and Putraja-
ya Hospital from September 2005 to May 
2012. The study was conducted in accord-
ance with the ethical rules and policies of 
both the centres. Patients enrolled in this 
study were evaluated by rheumatologists 
and/or orthopaedic surgeons. The diagnosis 
of primary osteoarthritis of the knee (OAK) 
was established based on history, physical 
examination and radiographic findings of 
OAK. The criteria to be classified as OAK 
included knee pain, osteophytes and at least 
1 of the following 3; age >50 years, early 
morning stiffness of <30 minutes duration 
or crepitus (Altman et al., 1986). The radio-
graphs of the knees were assessed and 
graded according to the Modified Kellgren 
Lawrence grade (Petersson et al., 1997). 
The grade for the most severe tibiofemoral 
compartment was recorded. Besides, the 
radiographs were reviewed for total knee 
replacement (TKR) implants, in addition to 
the history of TKR from the cases. 
All controls had no clinical history, 
physical examination or radiographic find-
ings of OAK. The medical records of all 
cases and controls were reviewed. Those 
with documented autoimmune disorder 
were excluded from this study. 
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ANA assay 
All subjects were tested for antinuclear 
antibodies (ANA). The ANA was detected 
by indirect immunofluorescence testing by 
HEp-2 human epithelial cells, and a titer of 
1:40 and above was considered positive. 
Multispot slides with fixed HEp-2 cells 
were incubated with diluted sera for 30 min 
at room temperature. Figure 1 shows the 
micrographs of the immunofluorescence 
patterns identified. To ensure that both the 
cases and controls had no undiagnosed au-
toimmune disorder that could influence the 
results, serum was checked for rheumatoid 
factor, anti-smooth muscle, anti-mitochon-
drial, antidouble stranded DNA, extractable 
nuclear antibodies, lupus anticoagulant and 
anticardiolipin antibodies among subjects 
who tested ANA positive. One control had 
positive antidouble stranded DNA and 5 
cases had positive extractable nuclear anti-
bodies and were excluded from the statisti-
cal analysis. 
 
Homogenous         Nucleolar 
   
Speckled          Centromere 
  
Figure 1: Micrographs of the immunofluores-
cence staining patterns. HEp-2 cells were incu-
bated with diluted sera for 30 min at room tem-
perature. Representative staining patterns are 
shown. 
Statistical analysis 
Data analysis was performed using the 
SPSS 17.0 software for Windows. Data are 
shown as number of cases, percentages, 
mean ± SD and median (range). We used 
the Fisher’s exact probability test and Chi 
square test for comparison of categorical 
variables whereas the student T test and 
Mann–Whitney U test for comparison of 
mean and median values respectively. Bina-
ry logistic regression analysis was per-
formed to identify the parameters which 
were significantly associated with the ANA. 
A p value of <0.05 was considered statisti-
cally significant. 
 
RESULTS 
ANA positivity 
The baseline characteristics of the 132 
cases and 63 controls studied are shown in 
Table 1. More than half of the cases and 
controls were females. The incidence of 
ANA positivity among the cases (39.4 %) 
was higher than the controls (27 %). This 
difference, although interesting, was not 
statistically significant (p=0.754). Similar-
ly, although the median ANA titre was 
higher among the cases (1:320), the differ-
ence was not of statistical significance 
(p=0.550). There were 5 immunofluores-
cence patterns detected i.e speckled, ho-
mogenous, nucleolar, centromere and 
mixed pattern (combination of 2 or 3 of the 
earlier patterns). Intriguingly, among the 
ANA positive subjects, the most commonly 
observed immunofluorescence staining pat-
tern was speckled for both cases and con-
trols. Almost half (44.2 %) of ANA positive 
OAK patients exhibited the speckled pat-
tern (Figure 2). 
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Table 1: Demographic data of the study population 
Characteristic Cases  
n=132 (%) 
Controls  
n=63 (%) 
p value 
Mean age, years (SD) 62.51 ± 9.17* 60.37 ± 8.21* 0.117 
Race     
 Malay 83 (62.9) 40 (63.5) 0.152 
 Chinese 25 (18.9) 12 (19.0)  
 Indian 24 (18.2) 11 (17.5)  
Gender    
 Male 41 (31.1) 12 (19.0) 0.087 
 Female 91 (68.9) 51 (81.0)  
ANA positivity 52 (39.4) 17 (27.0) 0.754 
Median ANA titre (range) 1:320 (1:40-640)** 1:160 (1:40-640)** 0.550 
*Data expressed as mean ± standard deviation, **Data expressed as median (range) 
 
Table 2: Comparison between the ANA positive group and ANA negative group of patients with  
primary osteoarthritis of the knee 
Characteristic ANA positive 
n=52 (5) 
ANA negative 
n=80 (%) 
p value 
Mean time since osteoarthritis  
diagnosis, years (SD) 
5.63 ± 2.42* 6.31 ± 3.01* 0.174 
Mean BMI, kg/m2(SD) 29.12 ± 4.81* 30.33 ± 4.74* 0.157 
Bilateral involvement of the knees 36 (69.2) 16 (20.0) <0.001 
Modified Kellgren–Lawrence grade in  
most severe tibiofemoral compartment 
   
 Grade II 9 20 0.003 
 Grade III 12 36  
 Grade IV 31 24  
Treatment    
 Supportive therapy 33 (63.0) 67 (84.0) 0.012 
 Total knee replacement 19 (36.5) 13 (16.3)  
 Unilateral 13 11  
 Bilateral 6 2  
Tibiofemoral compartment with more  
severe features of osteoarthritis 
   
 Medial 39 (75.0) 61 (76.3) 1.000 
 Lateral 13 (25.0) 19 (23.8)  
*Data expressed as mean ± standard deviation 
Figure 2: The immunofluorescence 
staining pattern among cases and con-
trols. Figures represent the numbers of 
positive cases in each category. 
EXCLI Journal 2012;11:624-631 – ISSN 1611-2156 
Received: August 12, 2012, accepted: September 04, 2012, published: September 07, 2012 
 
628 
Table 3: Regression analysis of the relationship of ANA positivity with bilateral, severe knee involve-
ment and the frequency of TKR 
 Odds ratio 95 % confidence interval p value 
Bilateral OAK 9.000 4.026 to 20.117 < 0.001 
Grade IV OAK 3.444 1.657 to 7.160 < 0.001 
TKR 2.967 1.308 to 6.734   0.009 
 
 
 
Effects of ANA positive status on knee in-
volvement and the frequency of total knee 
replacement (TKR) among OAK patients 
Table 2 outlines the differences between 
the ANA positive and ANA negative cases. 
According to the World Health Organiza-
tion classification, the mean BMI of the 
ANA positive patients (29.12 kg/m2) fell 
under the pre-obese category (25.00-
29.99 kg/m2) whereas the ANA negative 
group (30.33) was in the Obese Class I cat-
egory (30.00-34.99) (WHO Expert Consul-
tation, 2004)). However, the difference in 
the mean BMI between both the groups was 
statistically insignificant (p=0.157). Despite 
the lower BMI, the ANA positive OAK pa-
tients showed significantly higher incidence 
of bilateral disease with higher grade of 
OAK and higher frequency of TKR with 
p values of <0.001, 0.003 and 0.012 respec-
tively. In the multiple regression analysis 
model, bilateral OAK (p< 0.0001; odds ra-
tio 9.00), Grade IV OAK (p<0.001, odds 
ratio 3.44) and TKR (p=0.009; odds ratio 
2.97) remained associated with ANA posi-
tivity (Table 3). 
 
DISCUSSION 
The concept of autoimmunity in OA is 
barely a few decades old. The pathophysi-
ology of OA does involve cytokines and 
growth factors but probably to a lesser ex-
tent than in RA. It has been postulated that 
interleukin 1 and tumour necrosis factor-
beta activate enzymes that accelerate prote-
olytic digestion of cartilage. Growth factors 
such as tissue growth factor-beta and insu-
lin growth factor-1 are believed to interfere 
with the physiological processes of carti-
lage synthesis and repair. An imbalance be-
tween cartilage synthesis and catabolism 
with more of the latter results in OA 
(Creamer and Hochberg, 1997; Manek and 
Lane, 2000). More recently, Scanzello et al. 
(2008) describe OA as a chronic wound 
with the activation of Toll-like receptors 
and their signaling pathways. To date, there 
are less than 40 human studies focusing on 
the autoimmunity aspect of OA, based on 
our literature search. This study, therefore, 
attempted to address the paucity of research 
in this area by exploring the significance of 
ANA among paients with OAK. ANA test 
is a simple immunological investigation 
which is readily available to clinicians 
worldwide.  
The incidence of ANA positivity in this 
study among the cases and controls were 
higher than that of the general population 
which is reported to be between 5 to 15 % 
(Mariz et al., 2011; Azizah et al., 1996; 
Forslid et al., 1994). A possible explanation 
for this is the higher mean age of this study 
population which is in the 6th decade of life. 
The prevalence of ANA positivity among 
healthy people increases with age (Oyeyin-
ka et al., 1995; Xavier et al., 1995). The au-
toantibodies detected in the controls could 
be the expression of age-related damaged 
tissue process rather than subclinical auto-
immunity, as suggested by previous data 
concerning aging process and circulating 
antibodies (Stone, 1990; Candore et al., 
1997). 
The novel findings of this study are the 
associations of ANA positivity with higher 
occurrence of bilateral primary OAK, 
Grade IV OAK and rate of TKR. The exact 
mechanism for these links is a mystery 
which will hopefully be unlocked by de-
tailed research in years to come. It is tempt-
ing to speculate that ANA positivity in 
OAK is associated with higher levels of 
proinflammatory cytokines (IL-1beta, IL-6, 
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IL-12, IL-18 and TNF-alpha) owing to T 
cell activation based on knowledge derived 
from studies on ANA in other diseases such 
as depressive disorder, hepatitis C and sub-
acute cutaneous lupus erythematosus (Maes 
et al., 1991; Atta et al., 2010; Maczynska et 
al., 2006). As a consequence of the afore-
mentioned, the ANA positive OAK patients 
probably undergo more accelerated joint 
damage compared to their ANA negative 
counterparts.  
The speckled pattern of immunofluores-
cence staining occurred at highest frequen-
cy among cases and controls. This result 
echoes the finding of other studies which 
have concluded that ANA immunofluores-
cent pattern lack specificity (Malleson et 
al., 1997; Wangel et al., 1984). The ANA 
titre was not very useful either in distin-
guishing OAK patients from the healthy 
controls. High ANA titres of equal to or 
more than 1:640 have a positive predictive 
value for an autoimmune disease (Malleson 
et al., 2010). These similarities between the 
cases and controls remind us that although 
autoimmunity may contribute to the patho-
genesis of primary OAK, OA still does not 
qualify to be labelled as an autoimmune 
disease. 
In conclusion, this case-controlled study 
suggests that ANA test is a potential prog-
nostic tool in primary OAK. ANA positivi-
ty is associated with less favorable disease 
outcomes such as bilateral, Grade IV OAK 
and the need for TKR. Nevertheless, this 
discovery merits further research with pref-
erably large prospective cohort studies. 
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